Get the Stockscreener App
47.06
7.91%
-4.04
After Hours:
47.95
0.89
+1.89%
Harrow Inc stock is traded at $47.06, with a volume of 848.03K.
It is down -7.91% in the last 24 hours and up +22.42% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$51.10
Open:
$51.1
24h Volume:
848.03K
Relative Volume:
1.15
Market Cap:
$1.74B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-49.02
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+2.86%
1M Performance:
+22.42%
6M Performance:
+51.03%
1Y Performance:
+29.29%
1-Day Range:
$46.75
$51.30
1-Week Range:
$44.48
$51.30
52-Week Range:
$20.85
$51.30
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
47.06 | 1.89B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow Health stock hits 52-week high at 50.75 USD - Investing.com
Precision Trading with Harrow Health Inc. 11.875% Senior Notes Due 2027 (HROWM) Risk Zones - news.stocktradersdaily.com
Divisadero Street Capital Management LP Takes Position in Harrow, Inc. $HROW - MarketBeat
Aug Closing: Why Harrow Inc stock is favored by pension funds2025 Performance Recap & Daily Entry Point Trade Alerts - moha.gov.vn
Harrow (HROW) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Surrounding Harrow Is Evolving After Analyst Target Upgrades - Yahoo Finance
Can Harrow Inc. stock deliver strong Q4 earningsLong Setup & Safe Capital Growth Stock Tips - Newser
Panagora Asset Management Inc. Acquires Shares of 47,132 Harrow, Inc. $HROW - MarketBeat
155,465 Shares in Harrow, Inc. $HROW Acquired by Diametric Capital LP - MarketBeat
Harrow (NASDAQ:HROW) Shares Up 10.2%Time to Buy? - MarketBeat
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story - Yahoo Finance
Should Vevye’s CVS Formulary Win Prompt a Closer Look from Harrow (HROW) Investors? - simplywall.st
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha
Creative Planning Grows Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow, Inc. $HROW Shares Purchased by Geode Capital Management LLC - MarketBeat
Intech Investment Management LLC Sells 6,798 Shares of Harrow, Inc. $HROW - MarketBeat
Insider Sell: Why Harrow Inc. stock appeals to dividend seekersMarket Trend Review & Weekly High Return Stock Opportunities - moha.gov.vn
Market Trends: Is Harrow Inc. stock attractive for income investors - moha.gov.vn
How Harrow Health Inc. 8.625% Senior Notes Due 2026 (HROWL) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Harrow to Present at Two Investor Conferences in December - Sahm
Following a 2.8% Decline Over Last Year, Recent Gains May Please Harrow, Inc. (NASDAQ:HROW) Institutional Owners - 富途牛牛
Is Harrow Inc. stock attractive for income investorsBull Run & Daily Chart Pattern Signal Reports - moha.gov.vn
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% - Yahoo Finance
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge - The Motley Fool
A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance - Yahoo Finance
Why Harrow Inc. stock remains on watchlistsJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Health Care Notes: Analysts raise HCA price targets - Nashville Post
Should I hold or sell Harrow Inc. stock in 2025Portfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
Harrow, Inc. Hits Day High with 7.65% Surge in Strong Intraday Performance - Markets Mojo
How Harrow Inc. stock performs in rising dollar environment2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
How Harrow Inc. stock reacts to job market dataJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Harrow Inc. stockBear Alert & Momentum Based Trading Signals - newser.com
Can Harrow Inc. stock sustain market leadership2025 Price Momentum & AI Enhanced Trading Alerts - newser.com
Harrow, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:HROW) 2025-11-19 - Seeking Alpha
How Harrow Inc. stock performs in rate cut cyclesEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Harrow officially acquires Melt Pharmaceuticals - Eyes On Eyecare
Detecting price anomalies in Harrow Inc. with AIJuly 2025 Fed Impact & Consistent Profit Trading Strategies - newser.com
Will Harrow's (HROW) Return to Profitability Reshape Its Growth Narrative? - simplywall.st
Analyzing Harrow Inc. with risk reward ratio charts2025 Biggest Moves & Safe Swing Trade Setups - newser.com
Best data tools to analyze Harrow Inc. stockJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Harrow Completes Its Acquisition of Melt Pharmaceuticals - VisionMonday.com
What analysts say about Harrow Inc stockStock Price Targets & Affordable Growth Investments - earlytimes.in
Will Harrow Inc. stock pay special dividendsMarket Trend Report & Weekly Top Stock Performers List - newser.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
| BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):